TD Cowen Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price objective lowered by analysts at TD Cowen from $119.00 to $100.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical technology company’s stock. TD Cowen’s price objective points to a potential upside of 20.74% from the company’s current price.

A number of other analysts also recently issued reports on the company. Truist Financial cut their target price on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. BTIG Research raised shares of Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 price target on the stock in a research report on Wednesday, June 3rd. Argus dropped their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. Rothschild & Co Redburn cut their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $98.17.

Medtronic Trading Up 0.5%

Shares of Medtronic stock opened at $82.82 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock’s 50 day simple moving average is $79.02 and its 200-day simple moving average is $88.56. The stock has a market cap of $106.02 billion, a P/E ratio of 22.18, a P/E/G ratio of 2.20 and a beta of 0.56. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter last year, the firm earned $1.62 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic will post 5.94 EPS for the current fiscal year.

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medtronic

Several large investors have recently added to or reduced their stakes in MDT. Monetary Solutions Ltd purchased a new position in Medtronic in the 4th quarter valued at approximately $27,000. Lodestone Wealth Management LLC purchased a new stake in shares of Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic in the fourth quarter valued at $29,000. Finally, GoalVest Advisory LLC purchased a new position in Medtronic in the fourth quarter valued at $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: A Seeking Alpha article argues Medtronic’s conservative fiscal 2027 guidance is “built to be beaten,” saying recent revenue growth was the strongest in a decade and that catalysts such as the MiniMed separation, tariff refunds, and payment relief could create upside. Medtronic: Guidance Built To Be Beaten – Buy
• Positive Sentiment: Citi reportedly reiterated a buy rating, adding to the bullish analyst sentiment around Medtronic’s earnings power and long-term outlook. Medtronic (MDT) Receives a Buy from Citi
• Positive Sentiment: Another article says Medtronic could be undervalued, pointing to valuation models that suggest the shares may still have room to rise despite a long stretch of weak total returns. Medtronic (MDT) Stock Could Be 6% Undervalued On Fresh Deal News
• Positive Sentiment: A separate valuation piece says Medtronic may be about 9% undervalued, reinforcing the case that the stock could benefit if results continue to exceed cautious expectations. Medtronic (MDT) Could Be 9% Undervalued On Recall News
• Neutral Sentiment: Medtronic issued a voluntary global recall of its Octopus 4 Tissue Stabilizer due to an assembly issue affecting 590 units. The recall is a negative headline, but the limited scope and voluntary nature suggest contained impact for now. Medtronic (MDT) Recalls Octopus 4 Tissue Stabilizer After Manufacturing Assembly Issue

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).